Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

INTRODUCTION: Polymorphonuclear cell influx into the interstitial and bronchoalveolar spaces is a cardinal feature of severe coronavirus disease 2019 (COVID-19), principally mediated by interleukin-8 (IL-8). We sought to determine whether reparixin, a novel IL-8 pathway inhibitor, could reduce disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Piemonti, Lorenzo, Landoni, Giovanni, Voza, Antonio, Puoti, Massimo, Gentile, Ivan, Coppola, Nicola, Nava, Stefano, Mattei, Alessia, Marinangeli, Franco, Marchetti, Giulia, Bonfanti, Paolo, Mastroianni, Claudio Maria, Bassetti, Matteo, Crisafulli, Ernesto, Grossi, Paolo Antonio, Zangrillo, Alberto, Desai, Antonio, Merli, Marco, Foggia, Maria, Carpano, Marco, Schiavoni, Lorenzo, D’Arminio Monforte, Antonella, Bisi, Luca, Russo, Gianluca, Busti, Fabiana, Rovelli, Cristina, Perrotta, Elisabetta, Goisis, Giovanni, Gavioli, Elizabeth M., Toya, Sophie, De Pizzol, Maria, Mantelli, Flavio, Allegretti, Marcello, Minnella, Enrico Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600076/
https://www.ncbi.nlm.nih.gov/pubmed/37798468
http://dx.doi.org/10.1007/s40121-023-00871-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600076/
https://www.ncbi.nlm.nih.gov/pubmed/37798468
http://dx.doi.org/10.1007/s40121-023-00871-5

Ejemplares similares